4.8 Article

9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy

Journal

NATURE COMMUNICATIONS
Volume 12, Issue 1, Pages -

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s41467-021-25894-9

Keywords

-

Funding

  1. U.T. MD Anderson Cancer Center
  2. Andrew Sabin Family Foundation
  3. Doris Duke Clinical Scientist Development Award [2018097]
  4. MD Anderson Physician Scientist Award
  5. Khalifa Physician Scientist Award
  6. Andrew Sabin Family Foundation Fellows Award
  7. MD Anderson Faculty Scholar Award
  8. David H. Koch Center for Applied Research of Genitourinary Cancers [R01 CA254988]
  9. Wendy and Leslie Irvin Barnhart Fund
  10. Joan and Herb Kelleher Charitable Foundation

Ask authors/readers for more resources

This study found that the loss of 9p21.3 leads to a cold tumor immune phenotype, reducing the responsiveness of tumors to immune checkpoint therapy and resulting in worse outcomes. By incorporating 9p21 loss, PD-L1 expression, and TMB levels in pre-treatment tumors, a response score was derived that can accurately identify patients likely to achieve sustained response to therapy.
Immune checkpoint therapy (ICT) provides substantial clinical benefits to cancer patients, but a large proportion of cancers do not respond to ICT. To date, the genomic underpinnings of primary resistance to ICT remain elusive. Here, we performed immunogenomic analysis of data from TCGA and clinical trials of anti-PD-1/PD-L1 therapy, with a particular focus on homozygous deletion of 9p21.3 (9p21 loss), one of the most frequent genomic defects occurring in similar to 13% of all cancers. We demonstrate that 9p21 loss confers cold tumor-immune phenotypes, characterized by reduced abundance of tumor-infiltrating leukocytes (TILs), particularly, T/B/NK cells, altered spatial TILs patterns, diminished immune cell trafficking/activation, decreased rate of PD-L1 positivity, along with activation of immunosuppressive signaling. Notably, patients with 9p21 loss exhibited significantly lower response rates to ICT and worse outcomes, which were corroborated in eight ICT trials of >1,000 patients. Further, 9p21 loss synergizes with PD-L1/TMB for patient stratification. A response score was derived by incorporating 9p21 loss, PD-L1 expression and TMB levels in pre-treatment tumors, which outperforms PD-L1, TMB, and their combination in identifying patients with high likelihood of achieving sustained response from otherwise non-responders. Moreover, we describe potential druggable targets in 9p21-loss tumors, which could be exploited to design rational therapeutic interventions.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available